BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 12549986)

  • 1. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Type 2 diabetes mellitus and cardiovascular diseases: evaluation, treatment and prevention strategies].
    Mosseri MM; Fisman EZ; Tenenbaum A
    Harefuah; 2006 Feb; 145(2):141-6, 164. PubMed ID: 16509421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of coronary heart disease in type 2 diabetes.
    Mykkänen L
    Int J Clin Pract Suppl; 2000 Oct; (113):40-5. PubMed ID: 11965831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
    MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes.
    Boyne MS; Saudek CD
    Diabetes Care; 1999 Apr; 22 Suppl 3():C45-53. PubMed ID: 10189562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
    Rosenberg DE; Jabbour SA; Goldstein BJ
    Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial dysfunction and hypertension in diabetes mellitus.
    Dandona P; Chaudhuri A; Aljada A
    Med Clin North Am; 2004 Jul; 88(4):911-31, x-xi. PubMed ID: 15308385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prevention of cardiovascular disease in people with dysglycemia.
    Bianchi C; Miccoli R; Penno G; Del Prato S
    Diabetes Care; 2008 Feb; 31 Suppl 2():S208-14. PubMed ID: 18227487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
    McGuire DK; Newby LK; Bhapkar MV; Moliterno DJ; Hochman JS; Klein WW; Weaver WD; Pfisterer M; Corbalán R; Dellborg M; Granger CB; Van De Werf F; Topol EJ; Califf RM;
    Am Heart J; 2004 Feb; 147(2):246-52. PubMed ID: 14760321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
    Miranda VP; Rodrigues MJ; Gonçalves FR; Nunes JP
    Rev Port Cardiol; 2009 Oct; 28(10):1099-119. PubMed ID: 20058777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of diabetic patients with respect to prevention of macrovascular disease.
    Tkác T
    Acta Diabetol; 2003 Dec; 40 Suppl 2():S338-42. PubMed ID: 14704865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584214
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin in the early management of diabetic complications.
    Miles JM
    J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.